
Research Article

RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF EPROSARTAN MESYLATE IN PHARMACEUTICAL PREPARATIONS

Suresh Rewar^{1*}, Sharma A K², Bansal B K¹, Singh C J²

1. Department of pharmaceutics, Arya College of Pharmacy, Jaipur, Rajasthan, India

2. Department of pharmacology, Arya College of Pharmacy, Jaipur, Rajasthan, India

*Corresponding Author: Email sureshrewar1990@gmail.com

(Received: February 19, 2015; Accepted: March 25, 2015)

ABSTRACT

Objective: A simple, specific, accurate and precise Rp-high-performance liquid chromatography method was developed and validated for determination of Eprosartan Mesylate in pharmaceutical preparations.

Materials and Methods: The method showed a linear response for concentrations in the range of 2-12 µg/mL using Methanol: Acetonitrile: Buffer solution (Dissolve 0.02 M potassium di-hydrogen orthophosphate in water. Adjust pH of solution to 6.85 with orthophosphoric acid) in the ratio (45:45:10) as the mobile phase with detection at 233 nm and a flow rate of 1 mL/min and retention time 7.1 min. The value of correlation coefficient, slope and intercept were, 0.9998, 1661.8 and 114.82, respectively. The method was validated as per ICH guidelines for precision, recovery, ruggedness and robustness. The specificity of the method was investigated under different stress conditions including acidic, basic, photochemical and thermal as recommended by ICH guidelines.

Conclusions: The method was validated and successfully used for determination of the drugs in tablets.

Keywords: Eprosartan Mesylate, HPLC Determination.

INTRODUCTION

Eprosartan Mesylate (EPM) is a new antihypertensive agent as an angiotension II receptor antagonist that is highly selective to elicit a higher reduction in systolic blood pressure than other antihypertensive drugs. [1] The drug acts on the rennin angiotension system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotension II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic nor epinephrine production, further reducing blood pressure. [1,2] The rennin-angiotension system plays a vital role in the normal homeostatic regulation of cardiovascular and renal function. It is often activated in diseases such as hypertension, congestive heart failure and chronic renal failure and plays a central role in the pathophysiology of these disorders. [5]

Angiotensin II (All) receptor antagonists are a relatively new class of antihypertensive agent that block All Type 1 (AT(1)) receptors, and reduce the pressure effects of All in the vasculature.[4] Chemically, Eprosartan Mesylate (Fig.1) is a novel Angiotensin receptor antangonist [3] with chemical name IUPAC: (E)-2-Butyl - (1-Pcarboxy benzyl)- -2-thenylimidazole-5-acrylic acid methane sulfonate.




Fig.1: Eprosartan Mesylate

Its molecular weight is 520.61832 [g/mol] with molecular formula C₂₄H₂₈N₂O₇S₂.

Eprosartan is a non-peptide angiotensin II receptor antagonist which has been developed for the management of hypertension. [7]

Eprosartan alone or in combination with hydrochlorothiazide was highly effective and safe in lowering blood pressure, notably SBP, in older subjects with mild to moderate hypertension. [8] Control of systolic blood pressure should be the primary goal of treatment as it is increasingly recognized as a major determinant of cardiovascular risk. [6]

Stability indicating methods have become an important aspect of any analytical method validation and a part of US FDA requirements. Very few methods appeared in the literature in the spectrophotometric determination of Eprosartan Mesylate. [9] We have made an attempt to develop a new, simple, accurate stability indicating RP-HPLC method for the determination of Eprosartan in pure and tablet forms. The proposed method was validated as per ICH guidelines Q2A.[10]

MATERIALS AND METHODS

Chemicals: Eprosartan Mesylate was obtained as gift sample from Life Care Laboratories Pvt. Ltd. Hyderabad; The solvent used for the experiment was methanol (SD Fine Chem. Ltd. Mumbai). All chemicals were used as obtained without further purification.

Instrument: The analysis of drug was carried out on a Shimadzu HPLC system equipped with a reverse phase C18 column (150x4.6mm, 5 μ m in particle size), a 20 μ l injection loop and double beam UV-VIS spectrophotometer (Systronics India Limited UV-VIS Spectrometer-2203) was employed for spectrophotometric measurements.

METHODS

Chromatographic conditions: Separation was achieved at ambient temperature on a reversed phase column using a mobile-phase consisting of a mixture of Methanol: Acetonitrile: Buffer solution (Dissolve 0.02 M potassium dihydrogen orthophosphate in water. Adjust pH of solution to 6.85 \pm 0.05 with orthophosphoric acid) in the ratio (45:45:10). The mobile phase so prepared was filtered through 0.22 μ m nylon membrane filter and degassed by sonication. Flow rate of 1 mL / min was maintained.

Detection was carried out at 233 nm. The injection volume was 20 μ l for assay and degradation level.

Preparation of standard solutions: 100 mg of Eprosartan Mesylate working standard was accurately weighed and transferred to a 100 mL volumetric flask. Solution was sonicated and diluted up to the mark with mobile phase. A series of standard solutions in the concentration range of 20, 40, 60, 80, 100 and 120 μ g/ml were prepared followed by a suitable dilution of stock solution with the mobile phase.

Preparation of sample: 20 tablets were weighed and finely powdered. Blend equivalent to 50 mg of Eprosartan Mesylate was transferred to a 100 mL volumetric flask. About 60 mL of mobile phase was added and the solution was sonicated for 15 min and make up to the mark with mobile phase. The resulting solution was filtered through 0.22 μ m nylon membrane filter. The solution was mixed well and centrifuged at 2500 RPM for 10 min.

Preparation of calibration graph: The linearity of response for Eprosartan Mesylate assay method was determined by preparing and injecting solutions with concentrations of about 2, 4, 6, 8, 10 and 12 μ g/ml of Eprosartan Mesylate.

METHOD VALIDATION

Precision: Precision was measured in terms of repeatability of application and measurement. Repeatability of standard application was carried out using six replicates of the same standard concentration (6 μ g / mL for standard application). Repeatability of sample measurement was carried out in six different sample preparations from same homogenous blend of marketed sample (6 μ g /mL for sample application).It showed very low % relative standard deviation (% RSD) of peak area of Eprosartan Mesylate.

Accuracy: Accuracy (Recovery) study was performed by spiking 30, 50 and 70% of Eprosartan Mesylate working standard to a pre analyzed sample. The pre analyzed sample was weighed in such a way that final concentration is half or 50% of the sample preparation before spiking. The percentage sum level of preanalysed sample and spiked amount of drug should be 80, 100 and 120% of simulated dosages nominal or target concentration of sample preparation. The accuracy of the analytical method was established in duplicate across its range according to the assay procedure.

$$\% \text{ Recovery} = \frac{\% \text{ Amount Recovered}}{\% \text{ Sum Level}} \times 100$$

Ruggedness and robustness of the method: Method robustness and ruggedness was determined by analyzing same sample at normal operating conditions and also by changing some operating analytical conditions such as column make, mobile phase composition, flow rate, instrument and analyst. The robustness and ruggedness of the method was established as the % deviation from mean assay value obtain from precision study is less than $\pm 2.0\%$.

Analysis of marketed formulation: 20 tablets were weighed and finely powdered. Transfer blend equivalent to 100 mg of Eprosartan Mesylate to a 100 mL volumetric flask. Add about 60 mL of mobile phase and sonicate for 15 min and make up volume with mobile phase. Mix well and centrifuge the solution at 2500 RPM for 10 min. dilute the solution up to the desired concentration and inject it into the HPLC system.

FORCED DEGRADATION STUDIES

Preparation of acid and based- induced degradation

product: Tablet powder equivalent to 100 mg of Eprosartan Mesylate was transferred to 100 mL volumetric flask. To it, 10 mL of mobile phase was added and sonicated for 15 min with intermittent shaking. To it 5 mL of 1 N HCl was added and 5 mL of 1 N NaOH were added separately. The sample was heated on a boiling water bath for 30 min, cooled to room temperature and diluted to volume with mobile phase, mixed well. The acidic forced degradation and the alkaline forced degradation was performed in dark in order to exclude the possible degradative effect of light. This solution was centrifuged at 2500 rpm for 10 min and 5 mL of supernatant liquid was transferred to 25 mL volumetric flask, diluted to volume with mobile phase, mixed well and injected into the HPLC system.

Preparation of hydrogen peroxide – induced degradation

product: Tablet powder equivalent to 100 mg of Eprosartan Mesylate was transferred to 100 mL volumetric flask. To it, 10 mL of mobile phase was added and sonicated for 15 min with intermittent shaking. To it 5 mL of 3.0% H₂O₂ was added. The sample was heated on a boiling water bath for

30 min, cooled to room temperature and diluted to volume with mobile phase, mixed well. This solution was centrifuged at 2500 rpm for 10 min and 5 mL of supernatant liquid was transferred to 25 mL volumetric flask, diluted to volume with mobile phase, mixed well and injected into the HPLC system.

Photo-degradation product: Tablet powder equivalent to 100 mg of Eprosartan Mesylate (previously kept in UV light for 24 hr) was transferred to 100 mL volumetric flask. To it, 10 mL of mobile phase was added and sonicated for 15 min with intermittent shaking and diluted up to the mark with mobile phase. This solution was centrifuged at 2500 rpm for 10 min and 5 mL of supernatant liquid was transferred to 25 mL volumetric flask, diluted to volume with mobile phase, mixed well and injected into the HPLC system.

Thermal degradation product: Tablet powder equivalent to 100 mg of Eprosartan Mesylate was transferred to 100 mL volumetric flask. To it, 10 mL of mobile phase was added and sonicated for 15 min with intermittent shaking. The sample was heated on a boiling water bath for 30 min, cooled to room temperature and diluted to volume with mobile phase, mixed well. This solution was centrifuged at 2500 rpm for 10 min and 5 mL of supernatant liquid was transferred to 25 mL volumetric flask, diluted to volume with mobile phase, mixed well and injected into the HPLC. The specificity degradation study data for the determination of Eprosartan Mesylate and its degradants in pharmaceutical dosage form is given in Tables. The no stress treatment sample (as control) has been evaluated relative to the standard concentration where as rest of the stressed condition samples (Figures 8) is evaluated relative to the control sample with respect to the % assay and % degradation. The percentage degradation results are calculated by area normalization method.

Detection of the related impurities: Weigh and finely powder not less than 20 tablets. Transfer blend equivalent to 50 mg of Eprosartan Mesylate to a 50 mL volumetric flask. Add about 30 mL of mobile phase and sonicate for 20 min and make up volume with mobile phase. Mix well and centrifuge the solution at 2500 rpm for 10 min. The clear supernatant solution was injected into the HPLC system.

RESULTS AND DISCUSSION

Method of development: The chromatographic conditions were optimized with a view to develop a stability- indicating




Fig. 2: The simple chromatogram of standard Eprosartan Mesylate




Fig. 3: The simple chromatogram of test Eprosartan Mesylate




Fig. 4: The simple chromatogram of acid degraded sample




Fig. 5: The simple chromatogram of alkali degraded sample




Fig. 6: The simple chromatogram of Hydrogen Peroxide degraded sample




Fig.7: The simple chromatogram of UV degraded sample




Fig. 8: The simple chromatogram of Thermal degraded sample

Table 1: Regression characteristics of the proposed HPLC method

S. No.	Drug	Eprosartan Mesylate
1	Range($\mu\text{g/ml}$)	20-120 $\mu\text{g/ml}$
2	Detection wavelength (λ_{max})	233 nm
3	Mean R ² value	0.9998
4	Slope (m)	1661.8
5	Intercept (c)	114.82
6	Run time	10 min
7	Retention Time (min)	7.1
8	Theoretical Plates (N)	3276
9	Tailing Factor	1.02

Table 2: Method precision of Eprosartan Mesylate

Sample Preparation	% Assay Eprosartan Mesylate	% Deviation From Mean Assay value Eprosartan Mesylate
1	99.79	1.77
2	97.86	-0.16
3	98.04	0.02
4	97.26	-0.76
5	97.26	-0.76
6	97.92	-0.10
Mean \pm SD	98.02 \pm 0.93	
%RSD	0.95	

Table 3: Ruggedness and robustness of Eprosartan Mesylate

Parameter	Normal (Original)	Changed Conditions
Column Make	X Terra® RP18 column; 250x4.6mm;5µ	Luna C8 (Octylsilane), 250x4.6mm;5µ
Flow rate	1 mL/min	1.2mL/min
Mobile phase composition	(pH 6.85) Methanol: Acetonitrile: Buffer (KH ₂ PO ₄) (45:35:20)	(pH 6.50) Methanol: Acetonitrile: Buffer (KH ₂ PO ₄) (40:40:20)
Pump	Jasco PU -2080 plus series	Shimazdu LC-20AT
Detector	Jasco UV -2075 plus series	Shimazdu UV-VIS detector
% assay of Eprosartan Mesylate	98.02%	98.05%

Table 4: Recovery studies of Eprosartan Mesylate

Sample preparation	% simulated Dosage normal	% sum level	% amount recovered	% recovery
Preanalysed sample				99.02
1	80	80.46	81.18	100.90
2	80	79.98	81.19	101.52
1	100	100.90	101.52	100.61
2	100	101.08	101.50	100.41
1	120	121.24	121.85	100.50
2	120	121.04	121.70	100.54
Mean				100.75
± SD				0.41
% RSD				0.41

Table 5: Stressed Study Data of Eprosartan Mesylate

S. No.	Condition	% assay Eprosartan Mesylate	Retention time of drug	% Degradation
	No stress treatment	98.02	6.984	Nil
	Acid	99.19	4,4.78,5.95	0.09
	Alkali	99.77	4.34,5.86	0.07
	H ₂ O ₂	98.32	3.32,4.83,5.96	0.05
	UV	99.22	4.74,5.94,6.47	0.49
	Thermal	99.07	4.70	0.03

Table 6: Summaries of Forced Degradation Results

S. No.	Stress Condition	Time	% Assay of active substance	Mass balance (% assay+ % degradation products)	Remark
1	Acid degradation (1N HCl)	½ hr	99.76	99.4	No degradation products formed
2	Alkali degradation (1 N NaOH)	½ hr	99.88	99.3	No degradation products formed
3	H ₂ O ₂ degradation (3%)	½ hr	97.64	98.1	Mild degradation formed
4	UV degradation	24 hr	99.44	99.2	No degradation products formed
5	Thermal degradation (60°C)	½ hr	99.45	99.5	No degradation products formed

assay method. Two different columns were tried as under chromatographic conditions namely, XTerra® RP18, 250 x 4.6 mm, 5 µ (water, Ireland) and Luna C8 (Octylsilane), 250 x 4.6 mm, 5 µ (Phenomenax, USA). Luna C8 gave good peak shape but a lower retention with low peak purity. XTerra® RP18 column had given a good peak shape with response at affordable retention time with peak purity of Eprosartan Mesylate on higher side. The chromatographic conditions finally comprised of a mobile-phase in the ratio of Methanol: Acetonitrile: Buffer solution (Dissolve 0.02 M potassium dihydrogen orthophosphate in water. Adjust pH of solution to 6.85 ± 0.05 with ortho-phosphoric acid) in the ratio (45:45:10) at a flow rate of 1 mL / min using XTerra® RP18 column; 250 x 4.6 mm; 5 µ (G. L. Sciences, Japan) at 233 nm.

Calibration curve: These results indicate that the response is linear over the range of 2, 4, 6, 8, 10 and 12 µg/ml of Eprosartan with coefficient of regression, R^2 , value as 0.9998 as shown in Table: 1. The value of correlation coefficient, slope and intercept were 0.9998, 1661.8, and 114.82 respectively.

METHOD VALIDATION

Precision: The %RSD for repeatability of sample preparation is 0.95%. This shows that precision of the method is satisfactory as % relative standard deviation is not more than $\pm 2.0\%$. Table 2. Represent the precision of method.

Ruggedness and Robustness: Method robustness and ruggedness was determined by analyzing same sample at normal operating conditions and also by changing some operating analytical conditions such as column make, mobile phase composition, flow rate, instrument and analyst. The deliberate aforementioned changes in parameters alter the result of Eprosartan 0.03% to method precision study, which is not a significant change. The robustness and ruggedness of the method is established as the % deviation from mean assay value obtain from precision study is less than $\pm 2.0\%$.

Accuracy: The accuracy of the method was established by recovery studies. Results indicate that the individual recovery of Eprosartan ranges from 100.41% to 101.54% with mean recovery of 100.75% and % relative standard deviation of 0.41%. The recovery of Eprosartan by proposed method is

satisfactory as % relative standard deviation is not more than $\pm 2.0\%$ and mean recovery between 98.0 - 102.0%.

Analysis of the marketed formulation: The drug content was found to be 98.02% with a % RSD of 0.95%. It was noted that no degradation of Eprosartan had occurred in the marketed formulation that were analyzed by this method. The low RSD value indicated the suitability of this method for routine analysis of Eprosartan in pharmaceutical dosage form.

Stability- Indicating property: The stress studies were conducted and the data were depicted in (Table 5). The chromatogram of no stress treatment of control and sample showed no additional peaks (Figs. 2,3). The chromatogram of acid degraded sample showed additional peaks at retention time (RT) of 4.00, 4.78 and 5.95 min, respectively Fig.4. The chromatogram of alkali degraded sample showed additional peaks at RT of 4.34 min and 5.86 min, respectively Fig. 5. The chromatogram of hydrogen peroxide degraded sample showed additional peaks at RT of 3.32, 4.83 and 5.96 min respectively Fig. 6. The chromatogram of UV degraded sample showed additional peaks at RT of 4.74, 5.94 and 6.47 min, respectively Fig. 7. The chromatogram of thermal degraded sample showed additional peak at RT of 4.7 min Fig. 8. Rest of the peaks, if any, were from its blank or placebo in each of these specified conditions. In each forced degradation samples where additional peaks were observed, the response of the drug was changing from the initial control sample. This indicates that the drug is susceptible to acid-base hydrolysis degradation, hydrogen peroxide degradation, UV degradation and thermal degradation. The lower RT of the degraded component indicated that they were more polar than the analyte itself.

Detection of the related impurities: The sample solution showed no additional peak other than principal peak. Hence, related impurities are not present in the market sample.

CONCLUSION

The developed HPLC technique is precise, specific, accurate and stability indicating. Statistical analysis proves that the method is reproducible and selective for the analysis of Eprosartan in pharmaceutical dosage form. The method can be used to determine the purity of the drug available from

various sources. As the method separates the drug from its degradation products, it can be employed as a stability indicating one.

REFERENCES

1. Blankestijn PJ, Rupp H. Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker. *Cardiovascular & Hematological Agents in Medicinal Chemistry* 2008; 6: 253-257.
2. William H. Frishman, Angela Cheng-Lai, James Nawarskas, *the Current Cardiovascular Drugs*. 2007. p.53.
3. B. Pitt, M.A. Konstam, Overview of angiotensin II-receptor antagonists, *Am. J. Cardiol.* 82 (1998) 47S–48S.
4. Ruilope L, Jäger B.: Eprosartan for the treatment of hypertension, *Expert Opin Pharmacother.* (2003) Jan; 4(1):107-14.
5. Martin DE, Tompson D, Boike SC, et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. *Br J Clin Pharmacol.* (1997) 43:661.
6. McInnes GT.: Angiotensin II antagonists in systolic blood pressure control, *Hosp Med.* 2001 Dec; 62(12):773-7.
7. McClellan KJ, Balfour JA: Eprosartan. *Drugs* 1998; 55:713–718.
8. Conter HS, McKay DW, Reiz RJ. Eprosartan Mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting. *Can J Cardiol.* 2004 Oct; 20 Suppl C: 6C-10C.
9. M Kamila, N Mondal & L K Ghosh. Spectrophotometric determination of Eprosartan Mesylate in raw material and experimental tablets. *Indian Journal of Chemical Technology*, 2008, 15,194-196.
10. Carstensen J T and Rhodes C T, *Drug Stability*; 2nd Edn., Marcel Dekker, New York, 2008, 358.